{ "ok": true, "cik": "1162194", "ticker": "LAB", "name": "Standard BioTools Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-30", "items": [ "1.01 Entry into a Material Definitive Agreement", "1.02 Termination of a Material Definitive Agreement", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000114036126038110/0001140361-26-038110-index.htm" }, { "form": "10-Q", "filed": "2026-08-05", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526335103/0001193125-26-335103-index.htm" }, { "form": "8-K", "filed": "2026-08-05", "items": [ "2.02 Results of Operations and Financial Condition", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/0001193125-26-335106-index.htm" }, { "form": "8-K", "filed": "2026-07-28", "items": [ "1.01 Entry into a Material Definitive Agreement", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/0001140361-26-029841-index.htm" }, { "form": "8-K", "filed": "2026-07-24", "items": [ "3.01 Notice of Delisting or Failure to Satisfy a Listing Rule" ], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526316183/0001193125-26-316183-index.htm" }, { "form": "8-K", "filed": "2026-06-18", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526275946/0001193125-26-275946-index.htm" } ], "events12m": 15, "healthWatch": { "window": "last 12 months", "since": "2025-10-01", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 2, "latest": { "filed": "2026-07-24", "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526316183/0001193125-26-316183-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-06-18", "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526275946/0001193125-26-275946-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001162194.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1162194" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Standard BioTools Inc. ($LAB). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-30. 15 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 85331000, "revenueGrowth1y": -0.06237913150492269, "revenueGrowthPerYear": -0.1009026631789246, "yearsOfData": 5, "operatingMargin": -1.2920157973069577, "operatingMarginPrior": -1.4008109177215189, "netMargin": -0.877711499923826, "operatingCashFlow": -74343000, "capitalSpending": 8303000, "freeCashFlow": -82646000, "researchAndDevelopment": 25987000, "researchShareOfRevenue": 0.30454348361087996, "cash": 120863000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 130581000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 97948000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 106340000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 91008000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 85331000 } ], "totalEquity": 424291000, "totalAssets": 567754000, "equityRatio": 0.7473148581956269, "returnOnEquity": -0.1765203598473689, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -0.2, "sharesOutstanding": 381623000, "bookValuePerShare": 1.1118066783186549, "revenuePerShare": 0.2236002547016296, "range80": { "low": 54169830.82496061, "high": 112665013.39550528, "baseline": 80752779.02222998, "n": 749, "band": "b00", "bandLabel": "$50M–100M", "method": "v4.1", "credibility": 0.625, "growthYears": 6, "ownVolatility": 0.16192236857349462, "classVolatility": 0.19293522228976231, "volatility": 0.1742004116033646 }, "ifPaceHeld": { "low": 54169830.82496061, "high": 112665013.39550528 } }, "edgarette": "🔖 Exposure: revenue $85.3M (FY2025). Experience: revenue down 6.2% on the year, down 10.1% a year over 4 years; operating margin -129.2%, up from -140.1%. Soundness: equity 74.7% of assets, return on equity -17.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $54.2M and $112.7M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $55.7M to $109.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -129.2% against a -3.8% median; growth -6.2% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Standard BioTools (LAB) saw revenue fall 6.2% in FY2025 to $85 million, operating margin -129% against a -3.8% median for pharmaceutical preparations, equity 74.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Standard BioTools Inc. against its own record and its peers
Operating marginPeer median -3.8%-129.2%Revenue, on the yearPeer median 13.7%-6.2%Equity of assetsPeer median 40.3%74.7%Return on equityPeer median -1.1%-17.7%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 13, "hits": 10, "rate": 0.7692307692307693, "method": "v4", "byYear": { "2013": [ 1, 1 ], "2014": [ 1, 1 ], "2015": [ 0, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 1, 1 ], "2019": [ 1, 1 ], "2020": [ 1, 1 ], "2021": [ 0, 1 ], "2022": [ 0, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-01T14:02:34.553Z", "hash": "89ca7b1799794188", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Standard BioTools (LAB) saw revenue fall 6.2% in FY2025 to $85 million, operating margin -129% against a -3.8% median for pharmaceutical preparations, equity 74.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 85331000, "totalDebt": null, "cash": 120863000 }, "experience": { "revenueGrowth1y": -0.06237913150492269, "revenueGrowthPerYear": -0.1009026631789246, "operatingMargin": -1.2920157973069577, "operatingMarginPrior": -1.4008109177215189, "netMargin": -0.877711499923826, "freeCashFlow": -82646000 }, "soundness": { "equityRatio": 0.7473148581956269, "returnOnEquity": -0.1765203598473689, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-10-01", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 2, "latest": { "filed": "2026-07-24", "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526316183/0001193125-26-316183-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 4, "latest": { "filed": "2026-06-18", "url": "https://www.sec.gov/Archives/edgar/data/1162194/000119312526275946/0001193125-26-275946-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 54169830.82496061, "high": 112665013.39550528, "baseline": 80752779.02222998, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 749, "sizeBand": "$50M–100M", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341, "coverageAllYears": 0.6904374799277399, "stressCoverageAllYears": 0.819004992974709, "outcomeYears": [ 2019, 2025 ] }, "credibility": { "weightOnOwnRecord": 0.625, "growthYears": 6, "ownVolatility": 0.16192236857349462, "classVolatility": 0.19293522228976231, "pricedVolatility": 0.1742004116033646, "k": 3 }, "stress": { "low": 55683911.99459068, "high": 109807438.65352812, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 13, "hits": 10, "rate": 0.7692307692307693, "method": "v4", "byYear": { "2013": [ 1, 1 ], "2014": [ 1, 1 ], "2015": [ 0, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 1, 1 ], "2019": [ 1, 1 ], "2020": [ 1, 1 ], "2021": [ 0, 1 ], "2022": [ 0, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-01T14:02:34.553Z", "hash": "89ca7b1799794188", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001162194.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1162194" }, "speedCash": { "fiscalYear": 2025, "cashConversion": -0.8712, "growth3y": -0.0449, "volatility": 0.1619, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.7473, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "between", "inside": "Turns -87.1% of revenue into operating cash; revenue shrinking 4.5% a year over three years; no common dividend.", "outside": "Among $50M-100M companies: 11th percentile for cash, 24th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "$50M-100M", "cashPctInClass": 11, "growthPctInClass": 24, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±35%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 2, "name": "Weathered boat", "plain": "two warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -74343000, "investing": 27409000, "financing": 570000, "capitalSpending": 8303000, "free": -82646000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -44061000, "free": -57325000 }, { "fiscalYearEnd": "2022-12-31", "operating": -89370000, "free": -93195000 }, { "fiscalYearEnd": "2023-12-31", "operating": -43287000, "free": -46118000 }, { "fiscalYearEnd": "2024-12-31", "operating": -143454000, "free": -151809000 }, { "fiscalYearEnd": "2025-12-31", "operating": -74343000, "free": -82646000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 120863000, "shortTerm": 66712000, "longTerm": 25701000, "equityHoldings": null, "totalAssets": 567754000, "ladder": null, "currentRatio": 4.19, "unrealizedGain": 131000, "unrealizedLoss": 619000, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": -0.8712, "growth3y": -0.0449, "volatility": 0.1619, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.7473, "quadrant": { "code": "ss", "label": "Slow and steady", "plain": "growing slower than its size class, with steadier revenue" }, "compass": { "code": "between", "inside": "Turns -87.1% of revenue into operating cash; revenue shrinking 4.5% a year over three years; no common dividend.", "outside": "Among $50M-100M companies: 11th percentile for cash, 24th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "$50M-100M", "cashPctInClass": 11, "growthPctInClass": 24, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±35%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 2, "name": "Weathered boat", "plain": "two warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -74343000, "investing": 27409000, "financing": 570000, "capitalSpending": 8303000, "free": -82646000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -44061000, "free": -57325000 }, { "fiscalYearEnd": "2022-12-31", "operating": -89370000, "free": -93195000 }, { "fiscalYearEnd": "2023-12-31", "operating": -43287000, "free": -46118000 }, { "fiscalYearEnd": "2024-12-31", "operating": -143454000, "free": -151809000 }, { "fiscalYearEnd": "2025-12-31", "operating": -74343000, "free": -82646000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 120863000, "shortTerm": 66712000, "longTerm": 25701000, "equityHoldings": null, "totalAssets": 567754000, "ladder": null, "currentRatio": 4.19, "unrealizedGain": 131000, "unrealizedLoss": 619000, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }